Diagnosis and genetic testing analysis of limb-girdle muscular dystrophy type 2U caused by a compound heterozygous mutation in the ISPD gene
Received date: 2023-02-15
Revised date: 2023-05-10
Online published: 2023-05-19
Supported by
General Program of Natural Science Foundation of Fujian(2022J011072)
Limb-girdle muscular dystrophy (LGMD), a rare group of non-congenital inherited muscle diseases, is characterized by a progressive reduction in muscle tone and force of the proximal limbs. The clinical manifestations and genetic patterns of LGMD are heterogeneous. This study reported on a 10-year-old male patient with LGMD type 2U who experienced muscle weakness in the lower limbs after exercise. Upon admission, the patient's creatine kinase levels were significantly elevated, and hydration and alkalinization therapy were ineffective. Using high-throughput sequencing, muscular dystrophy-related genes were tested in the patient, his parents, and his sister. The patient was found to have a heterozygous deletion of exon 9 of the ISPD gene and a heterozygous missense mutation c.1231C>T (p.Leu411Phe). The patient's father carried the heterozygous missense mutation c.1231C>T (p.Leu411Phe) of the ISPD gene, while his mother and sister carried a heterozygous deletion of exon 9 of the ISPD gene. These mutations have not been reported in existing databases or literature. Conservation and protein structure prediction analyses of the mutation sites indicated that they are highly conserved and located in the C-terminal domain of the ISPD protein, which may affect protein function. Based on the above results and relevant clinical data, the patient was definitively diagnosed with LGMD type 2U. This study enriched the spectrum of ISPD gene mutations by summarizing the patient's clinical characteristics and analyzing new ISPD gene variations. This can aid in the early diagnosis and genetic counseling of the disease.
Key words: limb-girdle muscular dystrophy type 2U; ISPD gene; gene mutation
Juan Huang, Wenhua Miao, Xiaofeng Guo, Wei Ji . Diagnosis and genetic testing analysis of limb-girdle muscular dystrophy type 2U caused by a compound heterozygous mutation in the ISPD gene[J]. Hereditas(Beijing), 2023 , 45(6) : 536 -542 . DOI: 10.16288/j.yczz.22-329
| [1] | Wicklund MP, Kissel JT. The limb-girdle muscular dystrophies. Neurol Clin, 2014, 32(3): 729-749. |
| [2] | Liewluck T, Milone M. Untangling the complexity of limb-girdle muscular dystrophies. Muscle Nerve, 2018, 58(2): 167-177. |
| [3] | Chu M L, Ellen M. The limb-girdle muscular dystrophies: is treatment on the horizon? Neurotherapeutics, 2018, 15(4): 849-862. |
| [4] | Cirak S, Foley AR, Herrmann R, Willer T, Yau S, Stevens E, Torelli S, Brodd L, Kamynina A, Vondracek P, Roper H, Longman C, Korinthenberg R, Marrosu G, Nürnberg P, Consortium U, Michele DE, Plagnol V, Hurles M, Moore SA, Sewry CA, Campbell KP, Voit T, Muntoni F. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain, 2013, 136(Pt 1): 269-281. |
| [5] | Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC consortium on limb-girdle dystrophies. Neuromuscul Disord, 1995, 5(1): 71-74. |
| [6] | Angelini C. LGMD. Identification, description and classification. Acta Myol, 2020, 39(4): 207-217. |
| [7] | Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015, 17(5): 405-424. |
| [8] | Luo SS, Lu JH. Limb-girdle muscular dystrophy. Chin J Neurol, 2019, 52(7): 573-581. |
| [8] | 罗苏珊, 卢家红. 肢带型肌营养不良. 中华神经科杂志, 2019, 52(7): 573-581. |
| [9] | Muntoni F, Brockington M, Blake DJ, Torelli S, Brown SC. Defective glycosylation in muscular dystrophy. Lancet, 2002, 360(9343): 1419-1421. |
| [10] | Waite A, Brown SC, Blake DJ. The dystrophin- glycoprotein complex in brain development and disease. Trends Neurosci, 2012, 35(8): 487-496. |
| [11] | Yang H Y, Cai F, Liao H G, Gan S Y, Xiao T, Wu L W. Case report: ISPD gene mutation leads to dystroglycanopathies: genotype phenotype analysis and treatment exploration. Front Pediatr, 2021, 9: 710553. |
| [12] | Turan S, Farruggio AP, Srifa W, Day JW, Calos MP. Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Mol Ther, 2016, 24(4): 685-696. |
| [13] | Pedemonte N, Lukacs GL, Kai D, Caci E, Zegarra-Moran O, Galietta LJV, Verkman AS. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest, 2005, 115(9): 2564. |
| [14] | Carotti M, Marsolier J, Soardi M, Bianchini E, Gomiero C, Fecchio C, Henriques SF, Betto R, Roberta Sacchetto R, Richard L, Sandonà D. Repairing folding-defective a-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D. Hum Mol Genet, 2018, 27(6): 969-984. |
| [15] | Riemersma M, Froese DS, van Tol W, Engelke UF, Kopec J, van Scherpenzeel M, Ashikov A, Krojer T, von Delft F, Tessari M, Buczkowska A, Swiezewska E, Jae LT, Brummelkamp TR, Manya H, Endo T, van Bokhoven H, Yue WW, Lefeber DJ. Human ISPD is a cytidyltransferase required for dystroglycan O-mannosylation. Chem Biol, 2015, 22(12): 1643-1652. |
/
| 〈 |
|
〉 |